Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Nishanth Belugali Nataraj"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Mismatch repair proficient (MMRp) tumors of colorectal origin are one of the prevalent yet unpredictable clinical challenges. Despite earnest efforts, optimal treatment modalities have yet to emerge for this class. The poor prognosis and limited acti
Externí odkaz:
https://doaj.org/article/ea13ff97992c4eb4a8ffbac30c81c68c
Autor:
Anat Gershoni, Ori Hassin, Nishanth Belugali Nataraj, Sivan Baruch, Adi Avioz‐Seligman, Anna Chiara Pirona, Liat Fellus‐Alyagor, Tomer Meir Salame, Saptaparna Mukherjee, Giuseppe Mallel, Yosef Yarden, Yael Aylon, Moshe Oren
Publikováno v:
Molecular Oncology, Vol 17, Iss 12, Pp 2675-2693 (2023)
The core Hippo pathway module consists of a tumour‐suppressive kinase cascade that inhibits the transcriptional coactivators Yes‐associated protein (YAP) and WW domain‐containing transcription regulator protein 1 (WWTR1; also known as TAZ). Whe
Externí odkaz:
https://doaj.org/article/2dbf7e08c0fc4450b4c84ececd4af0cb
Autor:
Yael Aylon, Noa Furth, Giuseppe Mallel, Gilgi Friedlander, Nishanth Belugali Nataraj, Meng Dong, Ori Hassin, Rawan Zoabi, Benjamin Cohen, Vanessa Drendel, Tomer Meir Salame, Saptaparna Mukherjee, Nofar Harpaz, Randy Johnson, Walter E. Aulitzky, Yosef Yarden, Efrat Shema, Moshe Oren
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-20 (2022)
LATS1 is reported to regulate the transition of luminal-basal-like cell plasticity in breast cancer. Here the authors report that LATS1 limits the progression of luminal breast cancer by associating with NCOR1 nuclear corepressor to repress ERα-down
Externí odkaz:
https://doaj.org/article/4ccbb8ac8c2f4c92a83690814f9d6056
Autor:
Xiaoya Li, Birgitta Elisabeth Michels, Oyku Ece Tosun, Janine Jung, Jolane Kappes, Susanne Ibing, Nishanth Belugali Nataraj, Shashwat Sahay, Martin Schneider, Angelika Wörner, Corinna Becki, Naveed Ishaque, Lars Feuerbach, Bernd Heßling, Dominic Helm, Rainer Will, Yosef Yarden, Karin Müller-Decker, Stefan Wiemann, Cindy Körner
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-22 (2022)
Abstract Background MicroRNAs (miRNAs) and isomiRs play important roles in tumorigenesis as essential regulators of gene expression. 5’isomiRs exhibit a shifted seed sequence compared to the canonical miRNA, resulting in different target spectra an
Externí odkaz:
https://doaj.org/article/94cbefd9495f42afb45b540ee5bc32e6
Autor:
Ori Hassin, Nishanth Belugali Nataraj, Michal Shreberk-Shaked, Yael Aylon, Rona Yaeger, Giulia Fontemaggi, Saptaparna Mukherjee, Martino Maddalena, Adi Avioz, Ortal Iancu, Giuseppe Mallel, Anat Gershoni, Inna Grosheva, Ester Feldmesser, Shifra Ben-Dor, Ofra Golani, Ayal Hendel, Giovanni Blandino, David Kelsen, Yosef Yarden, Moshe Oren
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
The differential effects of TP53 missense mutations in colorectal cancer (CRC) remain to be explored. Here the authors compare the gain of function impact of two frequent TP53 mutations in CRC and show that p53R273 mutants control a transcriptional p
Externí odkaz:
https://doaj.org/article/a119b82dad0a479ebb369694272fe374
Autor:
Yael Aylon, Noa Furth, Giuseppe Mallel, Gilgi Friedlander, Nishanth Belugali Nataraj, Meng Dong, Ori Hassin, Rawan Zoabi, Benjamin Cohen, Vanessa Drendel, Tomer Meir Salame, Saptaparna Mukherjee, Nofar Harpaz, Randy Johnson, Walter E. Aulitzky, Yosef Yarden, Efrat Shema, Moshe Oren
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/d860069f12304f2f8bdcacb82805f013
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
Autor:
Ilaria Marrocco, Donatella Romaniello, Itay Vaknin, Diana Drago‐Garcia, Roni Oren, Mary Luz Uribe, Nishanth Belugali Nataraj, Soma Ghosh, Raya Eilam, Tomer‐Meir Salame, Moshit Lindzen, Yosef Yarden
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 4, Pp n/a-n/a (2021)
Abstract Some antibacterial therapies entail sequential treatments with different antibiotics, but whether this approach is optimal for anti‐cancer tyrosine kinase inhibitors (TKIs) remains open. EGFR mutations identify lung cancer patients who can
Externí odkaz:
https://doaj.org/article/f40e6d84396d426eb6294535a2d589ba
Autor:
Anjana Shenoy, Nishanth Belugali Nataraj, Gili Perry, Fabricio Loayza Puch, Remco Nagel, Irina Marin, Nora Balint, Noa Bossel, Anya Pavlovsky, Iris Barshack, Bella Kaufman, Reuven Agami, Yosef Yarden, Maya Dadiani, Tamar Geiger
Publikováno v:
Molecular Systems Biology, Vol 16, Iss 9, Pp n/a-n/a (2020)
Abstract Tumor relapse as a consequence of chemotherapy resistance is a major clinical challenge in advanced stage breast tumors. To identify processes associated with poor clinical outcome, we took a mass spectrometry‐based proteomic approach and
Externí odkaz:
https://doaj.org/article/5c738af05ac8485a9c300273476af2be
Autor:
Swati Srivastava, Nishanth Belugali Nataraj, Arunachalam Sekar, Soma Ghosh, Chamutal Bornstein, Diana Drago-Garcia, Lee Roth, Donatella Romaniello, Ilaria Marrocco, Eyal David, Yuval Gilad, Mattia Lauriola, Ron Rotkopf, Adi Kimchi, Yuya Haga, Yasuo Tsutsumi, Olivier Mirabeau, Didier Surdez, Andrei Zinovyev, Olivier Delattre, Heinrich Kovar, Ido Amit, Yosef Yarden
Publikováno v:
Cell Reports, Vol 29, Iss 1, Pp 104-117.e4 (2019)
Summary: The glucocorticoid receptor (GR) acts as a ubiquitous cortisol-dependent transcription factor (TF). To identify co-factors, we used protein-fragment complementation assays and found that GR recognizes FLI1 and additional ETS family proteins,
Externí odkaz:
https://doaj.org/article/47075bdf8b9148dfa3ecd25a83e31946
Autor:
Donatella Romaniello, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-Garcia, Itay Vaknin, Roni Oren, Moshit Lindzen, Soma Ghosh, Matthew Kreitman, Jeanette Clarissa Kittel, Nadege Gaborit, Gretchen Bergado Baez, Belinda Sanchez, Raya Eilam, Eli Pikarsky, Luis Paz-Ares, Yosef Yarden
Publikováno v:
Cancers, Vol 12, Iss 9, p 2394 (2020)
Although two growth factor receptors, EGFR and HER2, are amongst the best targets for cancer treatment, no agents targeting HER3, their kinase-defective family member, have so far been approved. Because emergence of resistance of lung tumors to EGFR
Externí odkaz:
https://doaj.org/article/11675062ac2d451c8ec22e88b30f6136